Subscribe
Core coverageQURE

Company profile / QURE

uniQure

Clinaptis stanceConstructive
ConvictionLow
Ticker
QURE
Exchange
NASDAQ
Coverage
Event-updated profile
Updated
Oct 3, 2026
Gene Therapy / Neurology

Gene-therapy company developing one-time treatments for severe neurological and genetic diseases. Its lead asset, ifezuntirgene inilparvovec (AMT-130), has been submitted for accelerated approval in Huntington’s disease, with earlier-stage programs in refractory mesial temporal lobe epilepsy and Fabry disease.

01 / Clinaptis view

The current read

Constructive, but less so after the four-year update.

  1. AMT-130’s 48-month data weakened what had been an unusually clean disease-modification narrative. In 12 high-dose patients, cUHDRS showed 44% slowing versus the updated external control and was no longer statistically significant (p=0.144), down materially from the earlier three-year estimate. TFC held up considerably better, with 61% slowing of functional decline (nominal p=0.008).
  2. The result therefore looks more like increased uncertainty around effect size and external-control reliability than evidence that the treatment effect disappeared. That interpretation is supported by the updated 36-month cohort of all 15 high-dose patients, which showed 80% slowing on cUHDRS and 67% on TFC.
  3. The regulatory distinction matters. FDA previously agreed that the 36-month dataset could serve as the primary basis for the accelerated-approval BLA, and the four-year results were not part of the submitted application. The investment case has nevertheless become higher risk: a small treated cohort, substantial attrition in the external control and materially different effect estimates depending on timepoint and comparator make the durability of the true treatment effect harder to estimate than it appeared before September 29.
02 / Consensus gap

Where the market may differ

The four-year update shifted the debate from whether AMT-130 works to how much confidence should be placed in the magnitude and durability of its effect.

  1. The selloff appropriately removed much of the valuation assigned to a clean continuation of the three-year trajectory. We think treating the 44% non-significant cUHDRS result as definitive evidence of waning efficacy goes too far: TFC remained comparatively stable, the updated 36-month dataset strengthened, and external-control attrition materially complicates the year-four comparison.
  2. But the opposite interpretation is also too generous. Post-hoc reconstruction with an earlier external control cannot erase the prespecified 48-month result. AMT-130 now needs FDA acceptance of the existing evidentiary package—and ultimately prospective confirmation—to resolve an uncertainty that another external-control sensitivity analysis cannot.
Coverage state
Event-updated profile
What the review turns on
Key variable

Whether FDA accepts the 36-month external-control evidence as sufficient for accelerated review despite the weaker and non-significant 48-month cUHDRS comparison.

Next catalyst

AMT-130 · FDA BLA acceptance, Priority Review determination and PDUFA date assignment · Early Nov 2026

03 / Pipeline

Key programs

3 assets · 3 programs

AssetIndicationStageNext event
Ifezuntirgene inilparvovec (AMT-130)
Huntington’s disease
BLA submitted / filing review
BLA acceptance and Priority Review decision · Early Nov 2026PDUFA date assignment following the 60-day filing review of the Sep 2 submission
AMT-260
Refractory mesial temporal lobe epilepsy
Phase 1/2a
Second-dose-cohort enrollment completion expected in Q3 2026; updated results expected in the first half of 2027
AMT-191
Fabry disease
Phase 1/2
Further safety evaluation following the protocol pause in mid- and high-dose enrollment after two asymptomatic liver-enzyme dose-limiting toxicities
04 / Connected research

Published on QURE

View full archive
  1. 01

    uniQure’s AMT-130: The FDA Changed Its Mind. The Data Didn’t.

    Projecting Four-Year cUHDRS and TFC Outcomes Ahead of AMT-130’s Q3 2026 BLA, Confirmatory Trial, and Commercial Launch in Huntington's Disease (HD)

    Read